NASDAQ:RGEN Repligen - RGEN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Repligen Co. Please log in to your account or sign up in order to add this asset to your watchlist. $180.17 -14.98 (-7.68%) (As of 01/30/2023 12:00 AM ET) Add Compare Share Share Today's Range$176.96▼$190.7650-Day Range$154.26▼$195.1552-Week Range$137.21▼$262.26Volume784,447 shsAverage Volume572,897 shsMarket Capitalization$10.00 billionP/E Ratio62.13Dividend YieldN/APrice Target$224.14 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Repligen MarketRank™ ForecastAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside24.4% Upside$224.14 Price TargetShort InterestBearish7.88% of Float Sold ShortDividend StrengthN/ASustainability-1.30Upright™ Environmental ScoreNews Sentiment0.31Based on 4 Articles This WeekInsider TradingSelling Shares$5 M Sold Last QuarterProj. Earnings Growth-7.26%From $3.17 to $2.94 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.99 out of 5 starsMedical Sector679th out of 1,049 stocksBiological Products, Except Diagnostic Industry104th out of 170 stocks 2.4 Analyst's Opinion Consensus RatingRepligen has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $224.14, Repligen has a forecasted upside of 24.4% from its current price of $180.17.Amount of Analyst CoverageRepligen has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.88% of the float of Repligen has been sold short.Short Interest Ratio / Days to CoverRepligen has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Repligen has recently increased by 11.20%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRepligen does not currently pay a dividend.Dividend GrowthRepligen does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRepligen has received a 69.02% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Spin filters", "Protein gels", and "Chromatography columns" products. See details.Environmental SustainabilityThe Environmental Impact score for Repligen is -1.30. Previous Next 2.4 News and Social Media Coverage News SentimentRepligen has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Repligen this week, compared to 3 articles on an average week.Search Interest16 people have searched for RGEN on MarketBeat in the last 30 days. This is an increase of 433% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Repligen to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Repligen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,000,000.00 in company stock.Percentage Held by InsidersOnly 1.10% of the stock of Repligen is held by insiders.Percentage Held by Institutions91.00% of the stock of Repligen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Repligen are expected to decrease by -7.26% in the coming year, from $3.17 to $2.94 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Repligen is 62.13, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 137.06.Price to Earnings Ratio vs. SectorThe P/E ratio of Repligen is 62.13, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 153.22.Price to Earnings Growth RatioRepligen has a PEG Ratio of 9.49. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRepligen has a P/B Ratio of 5.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Repligen (NASDAQ:RGEN) StockRepligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration, Process Analytics, and Proteins. The Chromatography product includes a range of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The Process Analytics products complement and support filtration, chromatography and proteins in-line absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. The Proteins product franchise is represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of virtually all mAb-based drugs on the market. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.Read More Receive RGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter. Email Address RGEN Stock News HeadlinesJanuary 26, 2023 | americanbankingnews.comRepligen (NASDAQ:RGEN) Sees Unusually-High Trading VolumeJanuary 25, 2023 | americanbankingnews.comAnalyzing Repligen (NASDAQ:RGEN) and ProKidney (NASDAQ:PROK)January 31, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 23, 2023 | americanbankingnews.comRepligen Co. (NASDAQ:RGEN) Receives $224.14 Average PT from AnalystsJanuary 21, 2023 | finance.yahoo.comRepligen (NASDAQ:RGEN) stock performs better than its underlying earnings growth over last five yearsJanuary 13, 2023 | finance.yahoo.comDo Options Traders Know Something About Repligen (RGEN) Stock We Don't?January 12, 2023 | finance.yahoo.comWhy Shares of Repligen Rose This WeekJanuary 12, 2023 | finance.yahoo.comHZNP vs. RGEN: Which Stock Is the Better Value Option?January 31, 2023 | UNKNOWN (Ad)Become an Investor in Brooklyn GinAward winning super-premium craft gin and upcoming Brooklyn distilleryJanuary 3, 2023 | finance.yahoo.comRepligen Corporation to Present at 41st Annual J.P. Morgan Healthcare ConferenceJanuary 1, 2023 | reuters.comRGEN.OQ - Repligen Corp | Stock Price & Latest News | ReutersDecember 18, 2022 | seekingalpha.comRepligen: Valuation Still A Concern, No Change To Hold ThesisDecember 7, 2022 | finance.yahoo.comDespite Attractive End Markets, Analyst Outlines Concerns For Repligen StockNovember 23, 2022 | finance.yahoo.comBIIB or RGEN: Which Is the Better Value Stock Right Now?November 21, 2022 | finance.yahoo.comDeclining Stock and Decent Financials: Is The Market Wrong About Repligen Corporation (NASDAQ:RGEN)?November 7, 2022 | finance.yahoo.comBIIB vs. RGEN: Which Stock Is the Better Value Option?November 1, 2022 | finance.yahoo.comRepligen (RGEN) Q3 Earnings and Revenues Top EstimatesNovember 1, 2022 | finance.yahoo.comRepligen Extends and Expands Long-Term Supply Agreement with Purolite for Affinity LigandsNovember 1, 2022 | finance.yahoo.comRepligen Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Financial GuidanceOctober 31, 2022 | finance.yahoo.comWill Repligen (RGEN) Beat Estimates Again in Its Next Earnings Report?October 18, 2022 | finance.yahoo.comShould You Invest in Repligen Corporation (RGEN)? - Yahoo FinanceOctober 12, 2022 | finance.yahoo.comRepligen to Report Third Quarter 2022 Financial Results - Yahoo FinanceOctober 12, 2022 | benzinga.comThe Worldwide Downstream Processing Industry is Expected to Reach $92 Billion by 2030 - BenzingaOctober 12, 2022 | globenewswire.comRepligen to Report Third Quarter 2022 Financial Results - GlobeNewswireOctober 12, 2022 | finance.yahoo.comRepligen to Report Third Quarter 2022 Financial ResultsOctober 11, 2022 | nasdaq.comIf EPS Growth Is Important To You, Repligen (NASDAQ:RGEN) Presents An OpportunityOctober 6, 2022 | marketwatch.com4 under-the-radar stock picks from a five-star fund manager who sees rewards that are worth the risks - MarketWatchSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter. Email Address RGEN Company Calendar Last Earnings11/01/2022Today1/30/2023Next Earnings (Estimated)2/16/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:RGEN CUSIP75991610 CIK730272 Webwww.repligen.com Phone(781) 250-0111Fax781-250-0115Employees1,852Year Founded1981Price Target and Rating Average Stock Price Forecast$224.14 High Stock Price Forecast$275.00 Low Stock Price Forecast$180.00 Forecasted Upside/Downside+24.4%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)$2.90 Trailing P/E Ratio62.13 Forward P/E Ratio56.84 P/E Growth9.49Net Income$128.29 million Net Margins20.76% Pretax Margin25.08% Return on Equity10.98% Return on Assets8.14% Debt Debt-to-Equity RatioN/A Current Ratio2.32 Quick Ratio1.73 Sales & Book Value Annual Sales$670.53 million Price / Sales14.92 Cash Flow$3.76 per share Price / Cash Flow47.90 Book Value$31.65 per share Price / Book5.69Miscellaneous Outstanding Shares55,520,000Free Float54,913,000Market Cap$10.00 billion OptionableOptionable Beta1.05 Social Links Key ExecutivesMr. Anthony J. Hunt (Age 59)Pres, CEO & Director Comp: $2.1MMr. Jon K. Snodgres (Age 57)Chief Financial Officer Comp: $860.08kMr. James R. Bylund (Age 59)Chief Operating Officer Comp: $725.55kMs. Christine Gebski (Age 54)Sr. VP of Filtration & Chromatography Comp: $685.06kMr. Ralf Kuriyel (Age 64)Sr. VP of R&D Comp: $708.15kMs. Sondra S. NewmanGlobal Head of Investor RelationsMs. Kimberly CornwellGlobal Head of Legal & Gen. CounselMr. Stephen TingleyVP & Head of Global SalesMs. Rachel GoodrichVP of MarketingMr. Craig HarrisonSr. VP of Process AnalyticsMore ExecutivesKey CompetitorsNeurocrine BiosciencesNASDAQ:NBIXHalozyme TherapeuticsNASDAQ:HALOExelixisNASDAQ:EXELSeagenNASDAQ:SGENQiagenNYSE:QGENView All CompetitorsInsiders & InstitutionsSumitomo Mitsui Trust Holdings Inc.Bought 130,685 shares on 1/30/2023Ownership: 0.235%Fort Washington Investment Advisors Inc. OHBought 1,815 shares on 1/30/2023Ownership: 0.003%New York State Teachers Retirement SystemBought 100 shares on 1/27/2023Ownership: 0.110%State of Michigan Retirement SystemBought 100 shares on 1/27/2023Ownership: 0.024%Ballentine Partners LLCSold 138 shares on 1/27/2023Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions RGEN Stock - Frequently Asked Questions Should I buy or sell Repligen stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RGEN shares. View RGEN analyst ratings or view top-rated stocks. What is Repligen's stock price forecast for 2023? 7 Wall Street analysts have issued 12-month target prices for Repligen's shares. Their RGEN share price forecasts range from $180.00 to $275.00. On average, they predict the company's share price to reach $224.14 in the next year. This suggests a possible upside of 24.4% from the stock's current price. View analysts price targets for RGEN or view top-rated stocks among Wall Street analysts. How have RGEN shares performed in 2023? Repligen's stock was trading at $169.31 on January 1st, 2023. Since then, RGEN shares have increased by 6.4% and is now trading at $180.17. View the best growth stocks for 2023 here. When is Repligen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023. View our RGEN earnings forecast. How were Repligen's earnings last quarter? Repligen Co. (NASDAQ:RGEN) released its earnings results on Tuesday, November, 1st. The biotechnology company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.09. The biotechnology company had revenue of $200.74 million for the quarter, compared to analyst estimates of $192.01 million. Repligen had a trailing twelve-month return on equity of 10.98% and a net margin of 20.76%. What guidance has Repligen issued on next quarter's earnings? Repligen updated its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided EPS guidance of $3.15-$3.20 for the period, compared to the consensus earnings per share estimate of $3.20. The company issued revenue guidance of $795.00 million-$805.00 million, compared to the consensus revenue estimate of $803.99 million. What is Tony J. Hunt's approval rating as Repligen's CEO? 13 employees have rated Repligen Chief Executive Officer Tony J. Hunt on Glassdoor.com. Tony J. Hunt has an approval rating of 52% among the company's employees. This puts Tony J. Hunt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Repligen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Block (SQ), Advanced Micro Devices (AMD), DocuSign (DOCU), Walt Disney (DIS), Netflix (NFLX), Tesla (TSLA) and ServiceNow (NOW). What is Repligen's stock symbol? Repligen trades on the NASDAQ under the ticker symbol "RGEN." Who are Repligen's major shareholders? Repligen's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Stephens Investment Management Group LLC (0.98%), Pendal Group Ltd (0.84%), New York State Common Retirement Fund (0.78%), Allspring Global Investments Holdings LLC (0.54%), Sumitomo Mitsui Trust Holdings Inc. (0.24%) and Comerica Bank (0.21%). Insiders that own company stock include Anthony Hunt, Christine Gebski, James Bylund, John Cox, Jon Snodgres, Karen A Dawes, Karen A Dawes, Manner Carrie Eglinton, Nicolas Barthelemy, Ralf Kuriyel and Thomas F Ryan Jr. View institutional ownership trends. How do I buy shares of Repligen? Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Repligen's stock price today? One share of RGEN stock can currently be purchased for approximately $180.17. How much money does Repligen make? Repligen (NASDAQ:RGEN) has a market capitalization of $10.00 billion and generates $670.53 million in revenue each year. The biotechnology company earns $128.29 million in net income (profit) each year or $2.90 on an earnings per share basis. How many employees does Repligen have? The company employs 1,852 workers across the globe. Does Repligen have any subsidiaries? The following companies are subsidiares of Repligen: ARTeSYN Biosolutions Holdings Ireland Limite, C Technologies Inc., Engineered Molding Technology LLC, Non-Metallic Solutions Inc, Repligen (Shanghai) Biotechnology Co. Ltd., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, Repligen Japan LLC, Repligen Korea Co. Ltd., Repligen Singapore Pte. Ltd., Repligen Sweden AB, and Spectrum Lifesciences LLC.Read More How can I contact Repligen? Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The official website for the company is www.repligen.com. The biotechnology company can be reached via phone at (781) 250-0111, via email at investors@repligen.com, or via fax at 781-250-0115. This page (NASDAQ:RGEN) was last updated on 1/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.